ESMO 2019 — Overview of Presidential Symposium II: breast cancer

  • Ben Gallarda
  • Oncology Conference reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

The second Presidential Symposium of ESMO 2019 included results from two trials of CDK4/6 inhibitors in HR+/HER2- breast cancer, a drastic improvement in early triple-negative breast cancer (TNBC) with add-on immunotherapy, and the latest advances in PARP inhibition.


Abemaciclib plus fulvestrant in patients with HR+, HER2- breast cancer:

  • Addition of abemaciclib resulted in a median OS of 46.7 vs 37.3 months with fulvestrant plus placebo (HR 0.757) and a median time to chemotherapy of 50.2 vs 22.1 months (HR 0.625, exploratory analysis).
  • Study included pre-, peri-, and post-menopausal patients, and benefit was seen in subgroups with poor prognoses, like visceral metastases.

Postmenopausal patients with HR+, HER2- breast cancer treated with fulvestrant plus ribociclib or placebo:

  • Overall median OS was not reached, vs 40.0 months with placebo (HR 0.724).
  • Patients with early relapse or receiving second-line (post-endocrine) therapy saw a median OS of 40.2 (vs 32.5 months, HR 0.730), and median OS was not reached in patients receiving first-line therapy (vs 45.1 months, HR 0.700).

Neoadjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab for TNBC:

  • With median follow-up of 15.5 months, pathological complete response (pCR) was 64.8% vs 51.2% with neoadjuvant chemotherapy plus placebo.
  • pCR rates improved in both PD-L1 positive (68.9% vs 54.9%) and PD-L1 negative (45.3% vs 30.3%) patients.
  • Full coverage on Univadis.

Veliparib with carboplatin and paclitaxel in HER2-, BRCA-mutated breast cancer:

  • Investigator-assessed median PFS was 14.5 vs 12.6 months with chemotherapy plus placebo (HR 0.705) and independent review committee-assessed median PFS was 19.3 vs 13.5 months (HR 0.695).
  • Interim median OS had not yet reached significance (33.5 vs 28.2 months, HR 0.945).